Guidance Drove Prices
Earnings season keeps making the same point: the quarter is a receipt, the outlook is the trade. With expectations already stretched, “conservative” guidance doesn’t land as prudence — it lands as demand uncertainty.
- Duolingo (DUOL) -12% after cutting its revenue outlook and striking a cautious tone. The product story didn’t crack. The forward slope did, and the stock paid for it.
- SanDisk (SAN) down after a revenue forecast below consensus. Same setup: investors hit visibility, not the rear-view print.
Mixed reports without a clean forward narrative mostly went nowhere.
- Hudson Technologies (HDSN) flat on GAAP EPS $0.12 ($0.06 miss) with revenue $78.3M ($4.1M beat).
- Primerica (PRI) flat on non-GAAP EPS $6.41 ($0.40 beat) and revenue $865M ($5.91M miss).
When macro isn’t giving the tape a tailwind, guidance quality becomes the differentiator. Tight ranges and crisp demand commentary pull buyers in. Extra fog turns the stock into a funding source.
AI: Proof vs Spend
AI flows split into two camps: show monetization, or justify the bill. The argument isn’t about whether AI matters — it’s about payback periods and who captures the economics.
Alphabet (GOOGL) down on news that Jeff Dean is leaving to start a new company. It doesn’t change the quarter, but talent and leadership headlines hit quickly when investors are already sensitive to platform durability. Call it a trim to the narrative premium, not a panic.
Figma up after beating earnings forecasts, pointing to adoption of AI agent products and better monetization. That’s what the market wants: features that attach, price, and show up in revenue — not a demo that wins a conference.
Cost of capital stayed front and center:
- Celestica (CLST) flat despite a $3B equity offering to fund data center expansion. Demand optimism ran into dilution and a higher hurdle rate. Equity-funded buildouts can work, but the bar is higher when capital isn’t cheap.
- SpaceX shares fell on details of heavy AI spending, including expected 2024 capex of $64B. Retail reportedly bought the dip. Institutions are modeling payback; retail is underwriting the story.
Defensives, Cleanly
Healthcare delivered the simplest “execute and get paid” action.
Eli Lilly (LLY) up after 48% revenue growth, driven by GLP-1 demand for Mounjaro and Zepbound. The takeaway wasn’t a one-quarter spike; it was scale that keeps repeating. When a demand engine keeps printing, the market stops debating it.
Biotech was less forgiving:
- Protagonist Therapeutics (PTGX) flat despite non-GAAP EPS $2.29 ($0.36 beat) because revenue $213.48Mmissed by $9.69M. In growth-driven names, an EPS beat doesn’t buy much time if the topline is slipping.
Adjacent defensives got rewarded for being straightforward:
- MetLife (MET) up after a Q2 earnings beat. In a tape punishing vague outlooks elsewhere, “no surprises” is the product.
What Mattered
- Guidance beat the quarter: DUOL and SAN got hit on forward visibility, not reported results.
- AI is bifurcating: monetization winners (Figma) versus companies defending spend and dilution (CLST, SpaceX).
- Defensive execution still clears: LLY showed durable demand; messy mixes like PTGX stalled.
- Macro remained a drag: Fed Governor Lisa Cook reiterated further rate action is possible if inflation stays elevated, keeping higher-for-longer embedded in the risk premium.
The market isn’t paying for stories — it’s paying for clarity on the next two quarters.